2024 annual financial data
Lyell Immunopharma 2024 Operating margin
Direct answer
Operating margin was -588,122.95%.
Operating income was -358,755,000 USD and net income was -342,994,000 USD.
Operating cash flow was -162,394,000 USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 61,000 USD
- Operating income
- -358,755,000 USD
- Net income
- -342,994,000 USD
- Operating cash flow
- -162,394,000 USD